Skip to main content

Table 2 Treatment and prognosis of COVID-19 Patients with and Without Influenza IgM positive

From: Clinical characteristics and outcome of influenza virus infection among adults hospitalized with severe COVID-19: a retrospective cohort study from Wuhan, China

Study Population

With influenza IgM positive (n = 73)

Without influenza IgM positive (n = 67)

Total (n = 140)

P value

Treatment in hospital

 Oxygen Therapy

 Nasal Cannula

32 (43.8)

29 (43.3)

61 (43.6)

0.9475

 Oxygen Mask

1 (1.4)

2 (3.0)

3 (2.1)

0.5069

 NMV/High-flow nasal cannula

35 (47.9)

34 (50.7)

69 (49.3)

0.7405

 IMV/ECMO

7 (9.6)

5 (7.5)

12 (8.6)

0.6535

 Drugs

  Oseltamivir

33 (45.2)

23 (34.3)

56 (40.0)

0.1894

  Arbidol

53 (72.6)

47 (70.1)

100 (71.4)

0.7482

  Compound Methoxamine capsule

17 (23.3)

6 (9.0)

23 (16.4)

0.0222

Clinical outcomes

 CURB-65

   

0.0397

  Low risk

65 (89.0)

50 (74.6)

115 (82.1)

  Medium risk

6 (8.2)

8 (11.9)

14 (10.0)

  High risk

2 (2.7)

9 (13.4)

11 (7.9)

 Duration of viral shedding, days

26.0 (20.0, 32.0)

25.0 (21.0, 32.0)

25.5 (20.5, 32.0)

0.9694

 Hospital length of stay, days

13.0 (10.0, 18.0)

14.0 (10.0, 17.0)

13.0 (10.0, 18.0)

0.9084

 Time from illness onset to discharge, days

27.0 (22.0, 35.0)

27.0 (21.0, 33.0)

27.0 (22.0, 33.5)

0.6208

 Death,No (%)

   

0.0276

  Discharge

70 (95.9)

57 (85.1)

127 (90.7)

  Death

3 (4.1)

10 (14.9)

13 (9.3)